• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by NewGenIvf Group Limited

    7/7/25 4:03:23 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care
    Get the next $NIVF alert in real time by email
    6-K 1 ea0248171-6k_newgen.htm REPORT OF FOREIGN PRIVATE ISSUER
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of July 2025

     

    Commission File Number: 001-42004

     

    NEWGENIVF GROUP LIMITED

     

    36/39-36/40, 13th Floor, PS Tower

    Sukhumvit 21 Road (Asoke)

    Khlong Toei Nuea Sub-district

    Watthana District, Bangkok 10110

    Thailand

    (Address of Principal Executive Offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒         Form 40-F ☐

     

     

     

     

     

    EXPLANATORY NOTE

     

    On July 4, 2025, the Board of Directors of NewGenIvf Group Limited (the “Company”), by written consent, in accordance with the applicable provisions of the Company’s existing memorandum and articles of association (“M&A”), and the laws of the British Virgin Islands, approved an amendment to the M&A to increase the authorized shares of the Company from a maximum of 50,000,000 shares with no par value, divided into: (a) 40,000,000 class A ordinary shares; (b) 9,995,000 class B ordinary shares; and (c) 5,000 preferred shares, to an unlimited number of shares with no par value, consisting of: (a) unlimited class A ordinary shares; (b) unlimited class B ordinary shares; and unlimited preferred shares (the “Amendment”). On July 4, 2025, upon filing of the Amendment with the Registry of Corporate Affairs of the British Virgin Islands, the Amendment became effective. A copy of the amended memorandum and articles of association is filed as Exhibit 3.1 to this Report. 

     

    On July 5, 2025, the Board of Directors of the Company approved a reverse stock split of all of the Company’s issued and unissued shares, including the Class A ordinary shares with no par value (the “Class A Ordinary Shares”), Class B ordinary shares with no par value and preferred shares with no par value, at an exchange ratio of one (1) share for five (5) shares (the “Reverse Stock Split”). Pursuant to the BVI Business Companies Act (as amended) and the Company’s M&A, the Company’s Board of Directors is authorized to effect the Reverse Share Split without the approval of the Company’s shareholders. Accordingly, no shareholder vote, consent or approval is required or will be sought in respect of the Reverse Share Split. The Company expects that the Reverse Stock Split will become effective on or around August 4, 2025, and that its Class A Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-Reverse Stock Split basis on such date.

     

    The Reverse Stock Split is intended for the Company to remain compliant with a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2).

     

    The Reverse Stock Split will reduce the number of outstanding Class A Ordinary Shares of the Company from approximately 7,029,880 to approximately 1,405,976 Class A Ordinary Shares. Every five (5) outstanding Class A Ordinary Shares will be combined into and automatically become one post-Reverse Stock Split Class A Ordinary Share. No fractional shares will be issued in connection with the Reverse Stock Split. Instead, the Company will issue one full post-Reverse Stock Split Class A Ordinary Share to any shareholder at a participant level who would have been entitled to receive a fractional share as a result of the process.

     

    After the Reverse Stock Split, all options, warrants and other convertible securities of the Company outstanding immediately prior to the Reverse Stock Split will be adjusted by dividing the number of Class A Ordinary Shares into which the options, warrants and other convertible securities are exercisable or convertible by five (5) in accordance with the terms of the plans, agreements or arrangements governing such options, warrants and other convertible securities and subject to rounding to the nearest whole share.

     

    No amendment to the Company’s M&A will be required to be made in relation to the Reverse Share Split, as (i) the Reverse Share Split will have no effect upon the par value of the ordinary shares, which is currently nil and will remain at nil after the Reverse Share Split is effected, and (ii) the number of shares authorized to be issued under the Company’s M&A is unlimited and therefore will not be affected by the Reverse Share Split.

     

    1

     

    EXHIBIT INDEX

     

    Exhibit   Description
    3.1   Amended Memorandum and Articles of Association of NewGenIvf Group Limited

     

    2

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: July 7, 2025

     

      NewGenIvf Group Limited
         
      By: /s/ Wing Fung Alfred Siu
      Name:  Wing Fung Alfred Siu
      Title: Chairman of the Board and Director

     

    3

    Get the next $NIVF alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NIVF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NIVF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Chardan Capital Markets Llc claimed ownership of 1,569,000 units of Class A Ordinary Shares (SEC Form 3)

    3 - NewGenIvf Group Ltd (0001981662) (Issuer)

    11/13/24 9:16:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NewGen Announces Strategic Acquisition of Cytometry Technology and Assets to Support Planned U.S. Expansion

    The new cytometry technology enhances accessibility, safety, and efficiency in sperm-sorting procedures The acquisition of 18 cell-sorting systems and associated patents positions NewGen for U.S. expansion, where over 430,000 IVF cycles took place in 2023 BANGKOK, July 29, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that it has acquired cytometry technology and assets including 18 fully-constructed cell-sorting and dispensing systems, eight partially constructed units, and six patents related to adva

    7/29/25 9:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Subsidiary Signs Memorandum of Understanding with Prominent UAE Real Estate Developer

    The agreement with BNW Real Estate Development LLC positions NewGenDigital to maximize the profitability of its recently acquired plot of land in the UAE Potential net return for the project is estimated to be as high as US$67 million per a feasibility study compiled by BNW BANGKOK, July 21, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that its subsidiary, NewGenDigital Limited ("NewGenDigital"), has signed a Memorandum of Understanding (the "MOU") with BNW Real Estate Development LLC ("BNW"), a prominent

    7/21/25 7:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Subsidiary Secures Strategic UAE Land and Begins Exploration of Potential Real World Asset Tokenization Initiative

    BANGKOK, July 01, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that its subsidiary, NewGenDigital Limited ("NewGenDigital"), has formally secured a strategic plot of land in Ras Al Khaimah's Beach District, UAE (the "Plot"), and is evaluating the feasibility of issuing digital tokens tied to the Plot as part of the Company's broader strategy to access blockchain-based asset digitization opportunities. This represents a significant milestone in the Company's previously announced US$45 million investment init

    7/1/25 7:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    SEC Filings

    View All

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    7/28/25 8:48:57 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    7/21/25 7:00:12 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    7/16/25 4:01:34 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Leadership Updates

    Live Leadership Updates

    View All

    NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director

    Company Granted Request to Continue its Listing on NasdaqAppoints Thorain Ko to Lead Business Development Initiatives BANGKOK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to specific conditions. Additionally, the Company announced the appointment of Mr. Thorain Ko as Business Development Director to drive its expansion initiatives. Nasdaq Listing UpdateThe Pane

    2/20/25 6:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    12/5/24 8:23:57 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    11/13/24 9:19:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    10/10/24 3:39:26 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care